Stiolto Respimat Launched for COPD

Stiolto Respimat Launched for COPD
Stiolto Respimat Launched for COPD

Boehringer Ingelheim announced the launch of Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Stiolto Respimat received approval from the Food and Drug Administration (FDA) in May 2015.

The Respimat inhaler actively delivers a slow-moving mist that aids the patient independent of inspiratory effort. Stiolto Respimat consists of tiotropium bromide, an anticholinergic, and olodaterol, a long-acting beta2-adrenergic agonist (LABA).

RELATED: New Inhaler Option for COPD Now Approved

Stiolto Respimat is available as a 3.124mcg/2.736mcg (equivalent to 2.5mcg/2.5mcg) strength. A carton contains one cartridge and one inhaler providing 60 metered actuations.

For more information call (800) 542-6257 or visit Stiolto.com.

Loading links....